Otros idiomas Shionogi & Co., Ltd.

Acciones

4507

JP3347200002

Diferido Japan Exchange Otros sitios de cotización 08:00:00 30/05/2024			Varia. Cinco días.	Varia. 1 de enero.
6.976 ^JPY	-0,20 %		+1,42 %	+2,62 %

14/05	El Nikkei japonés deriva lateralmente a la espera de más beneficios y del IPC estadounidense	RE
13/05	La japonesa Shionogi dice que el tratamiento para la COVID no cumplió el criterio de valoración en el ensayo de última fase	RE

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Shionogi & Co., Ltd. - Launch of the Gram-negative Bacterial Infection Treatment FETROJA 1g, in Taiwan	29/05
Japan's Nikkei drifts sideways as more earnings, US CPI awaited	14/05
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease	13/05
MÄRKTE ASIEN/Börsen wenig verändert - Mazda sehr schwach	13/05
MÄRKTE ASIEN/Uneinheitlich - Anleger meiden Risiken vor US-Preisdaten	13/05
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	13/05
Shionogi - Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund	09/05
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30/04
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	25/04
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23/04
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19/04
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19/04
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	19/04
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	18/04
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12/04
Shionogi Completes Up to 75 Billion Yen Share Buyback	29/03
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	28/03
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	22/03
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	21/03
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Shionogi & Co., Ltd.

Acciones

4507

JP3347200002

Otros idiomas

Filtros